These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31179082)

  • 1. Anaplastic lymphoma kinase inhibitors in non-small cell lung cancer patients with brain metastases: a meta-analysis.
    Zhang Z; Guo H; Lu Y; Hao W; Han L
    J Thorac Dis; 2019 Apr; 11(4):1397-1409. PubMed ID: 31179082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of ALK inhibitors on NSCLC brain metastases: A systematic review and pooled analysis of 21 studies.
    Petrelli F; Lazzari C; Ardito R; Borgonovo K; Bulotta A; Conti B; Cabiddu M; Capitanio JF; Brighenti M; Ghilardi M; Gianni L; Barni S; Gregorc V
    PLoS One; 2018; 13(7):e0201425. PubMed ID: 30052658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of brigatinib in
    Xing P; Hao X; Zhang X; Li J
    Front Oncol; 2022; 12():920709. PubMed ID: 36408160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of alectinib versus crizotinib on progression-free survival, central nervous system efficacy and adverse events in ALK-positive non-small cell lung cancer: a systematic review and meta-analysis.
    Yang YL; Xiang ZJ; Yang JH; Wang WJ; Xiang RL
    Ann Palliat Med; 2020 Jul; 9(4):1782-1796. PubMed ID: 32527124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Crizotinib, Ceritinib, and Alectinib in ALK-Positive Non-Small Cell Lung Cancer Treatment: A Meta-Analysis of Clinical Trials.
    Hoang T; Myung SK; Pham TT; Park B
    Cancers (Basel); 2020 Feb; 12(3):. PubMed ID: 32106398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALK Inhibitors in the Treatment of ALK Positive NSCLC.
    Khan M; Lin J; Liao G; Tian Y; Liang Y; Li R; Liu M; Yuan Y
    Front Oncol; 2018; 8():557. PubMed ID: 30687633
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of Efficacy and Safety of Brigatinib in First-Line Treatments for Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Systematic Review and Indirect Treatment Comparison.
    Yu Y; Zhu F; Zhang W; Lu S
    J Clin Med; 2022 May; 11(11):. PubMed ID: 35683354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials.
    Camidge DR; Kim DW; Tiseo M; Langer CJ; Ahn MJ; Shaw AT; Huber RM; Hochmair MJ; Lee DH; Bazhenova LA; Gold KA; Ou SI; West HL; Reichmann W; Haney J; Clackson T; Kerstein D; Gettinger SN
    J Clin Oncol; 2018 Sep; 36(26):2693-2701. PubMed ID: 29768119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis.
    Elliott J; Bai Z; Hsieh SC; Kelly SE; Chen L; Skidmore B; Yousef S; Zheng C; Stewart DJ; Wells GA
    PLoS One; 2020; 15(2):e0229179. PubMed ID: 32074131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceritinib Alone for Crizotinib-naive Versus Crizotinib-pretreated for Management of Anaplastic Lymphoma Kinase-rearrangement Non-Small-cell Lung Cancer: A Systematic Review.
    Zhao X; Feng Z; Wang G; Pang H; Wang M
    Clin Lung Cancer; 2018 Nov; 19(6):e945-e956. PubMed ID: 30228011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world treatment and prognostic factors for survival in ALK+ non-small cell lung cancer (NSCLC) patients with brain metastases in China.
    Li N; Xie M; Zhou Z; Sheng J; Yu X; Fan Y
    Thorac Cancer; 2023 Jan; 14(3):237-245. PubMed ID: 36411716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Smoking on Response to the First-Line Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis.
    Lin K; Lin J; Huang Z; Fu J; Yi Q; Cai J; Khan M; Yuan Y; Bu J
    Front Pharmacol; 2022; 13():881493. PubMed ID: 35645829
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of ceritinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer: A systematic review and meta-analysis.
    Tian W; Zhang P; Yuan Y; Deng XH; Yue R; Ge XZ
    J Clin Pharm Ther; 2020 Aug; 45(4):743-754. PubMed ID: 32369239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer.
    Reckamp K; Lin HM; Huang J; Proskorovsky I; Reichmann W; Krotneva S; Kerstein D; Huang H; Lee J
    Curr Med Res Opin; 2019 Apr; 35(4):569-576. PubMed ID: 30286627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of First-Line Treatment Strategies for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis.
    Peng L; Lu D; Xia Y; Hong S; Selvaggi G; Stebbing J; Sun Y; Liang F
    Front Oncol; 2021; 11():754768. PubMed ID: 34820326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
    Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
    Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed.
    Kuo CS; Tung PH; Huang AC; Wang CC; Chang JW; Liu CY; Chung FT; Fang YF; Guo YK; Yang CT
    BMC Cancer; 2021 Mar; 21(1):309. PubMed ID: 33761908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of alectinib in the treatment of ALK+ NSCLC: a systematic review and meta-analysis.
    Fan J; Xia Z; Zhang X; Chen Y; Qian R; Liu S; You D; Zhang J; Luo P
    Onco Targets Ther; 2018; 11():1105-1115. PubMed ID: 29535535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort.
    Bedas A; Peled N; Maimon Rabinovich N; Mishaeli M; Shochat T; Zer A; Rotem O; Allen AM; Bar J; Dudnik E;
    Oncol Res Treat; 2019; 42(5):275-282. PubMed ID: 30955009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
    Gettinger SN; Bazhenova LA; Langer CJ; Salgia R; Gold KA; Rosell R; Shaw AT; Weiss GJ; Tugnait M; Narasimhan NI; Dorer DJ; Kerstein D; Rivera VM; Clackson T; Haluska FG; Camidge DR
    Lancet Oncol; 2016 Dec; 17(12):1683-1696. PubMed ID: 27836716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.